PHARMACY

FDA approves Barr subsidiary’s generic form of Pfizer’s Camptosar

BY Alaric DeArment

MONTVALE, N.J. Food and Drug Administration has approved a generic version of Pfizer’s injected drug Camptosar, the drug’s manufacturer announced Monday.

PLIVA  Lachema, a subsidiary of Barr Pharmaceuticals, will market the drug in vials containing 20 mg per milliliter, 40 mg per two milliliters and 100 mg per five milliliters.

The drug, known generically as irinotecan hydrochloride, is used to treat metastatic carcinoma of the colon and rectum and brings Barr’s portfolio of injectables to nine products.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Treanda for treatment of Hodgkin’s disease

BY Alaric DeArment

FRAZER, Pa. The Food and Drug Administration has approved a drug for treating non-Hodgkin’s lymphoma, the drug’s manufacturer announced Monday.

Cephalon announced the agency’s approval of its drug Treanda (bendamustine hydrochloride), an injection for treating indolent B-cell NHL that has progressed up to six months following treatment with Rituxan (rituximab), made by Genentech and Biogen Idec, or a drug regimen that includes Rituxan.

Indolent NHL is a cancer of the lymphatic system that is not curable and often relapses after initial therapy. It affects about 30,000 people in the United States each year, according to the National Cancer Institute.

“Because most patients with indolent non-Hodgkin’s lymphoma eventually become resistant to existing treatments, new treatment options like Treanda are needed to improve patient outcome,” Georgetown University medicine professor and Treanda clinical investigator Bruce Cheson said in a statement.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

PharmaSmart to grow its blood pressure management systems in U.S. market

BY Michael Johnsen

ROCHESTER, N.Y. PharmaSmart International announced last week its intent to penetrate the U.S. market with its blood-pressure management program that has already enjoyed acceptance in the Canadian marketplace, boasting 75 percent penetration.

“Our goal as a company is to change the paradigm in community blood pressure screening,” stated Ashton Maaraba, PharmaSmart’s global vice president of sales and marketing. “We have committed significant resources to ensuring our clients execute at every level, delivering a turnkey program that delivers on the massive blood pressure management opportunity.”

Unlike existing blood pressure programs, which may primarily act as vehicles for third party advertising, PharmaSmart proposes to convert the hypertensive patient into a revenue-generating opportunity, and retain that consumer with an exclusive, pharmacy-branded BP management program, the company stated.

PharmaSmart’s blood pressure management tools and programs allow pharmacies to capitalize on the hypertension opportunity. PharmaSmart’s branded Smart Card offers pharmacists a long-term management tool for their patients that has been found to improve hypertension discovery, consultation, and prescription compliance, all significant challenges in the fight against hypertension, Maaraba noted.   

PharmaSmart’s “pharmacy first/patient first” platform seeks to augment the patient-pharmacist relationship through an education program—both point-of-sale training and continuing education—for pharmacists and pharmacy technicians around hypertension. The program includes PharmaSmart’s patented blood-pressure cuff, patient Smart Card management tool, and a patient web portal.

In Canada, PharmaSmart is present in Rexall, Shoppers Drug Mart, Wal-Mart Canada, Loblaws, Le Group Jean Coutu, Safeway Canada and Calgary Coop, among other pharmacies.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?